Study Title: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Sivapiragasam, Abirami, at sivapira@musc.edu.Study Coordinator, Gelardi, Theresa, at gelardi@musc.edu.Trial opened at the following institutions: Medical University of South Carolina